Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development

CRANBURY, N.J., March 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies. 

Eureka Therapeutics, headquartered in the San Francisco Bay Area, leverages its proprietary ARTEMIS^® cell receptor and E‑ALPHA^® antibody discovery platforms to drive innovation in safer, more effective T‑cell therapies. Through this collaboration, the two parties aim to accelerate Eureka's global clinical development by capitalizing on Porton Advanced's world-class cell and gene therapy manufacturing capabilities at their GMP sites.

Oliver Ju, Chairman of Porton Advanced, commented: "We are delighted to establish our partnership with Eureka. The seamless completion of the initial part of our collaboration program underscores our team's operational excellence and commitment to quality. Our continued collaboration will leverage our flexible models and state‑of‑the‑art manufacturing capabilities to expedite the development of groundbreaking advanced therapies."

Dr. Cheng Liu, Founder and CEO of Eureka Therapeutics, stated: "We are confident that through close collaboration with Porton Advanced, Eureka is well-positioned to accelerate our key pipeline programs, supported by Porton's robust and reliable manufacturing capabilities."

Accelerating Advanced Therapy Pipeline Development

Following the successful technology establishment, Porton Advanced will continue to support Eureka's Investigator-Initiated Trials (IITs) by providing CAR-T manufacturing services that adhere to stringent quality standards. These studies, supported by Porton Advanced's end-to-end CDMO platform, are designed to generate critical data for subsequent clinical milestones to further advance Eureka's innovative T-cell therapies.

Porton Advanced: Enabling Global Innovations in Advanced Therapies

Porton Advanced's proven process development capabilities, GMP-compliant facilities (meeting US, EU, and China standards), and extensive project experience position it as a strategic partner for international biotech companies seeking clinical and commercial CDMOs. This collaboration further validates Porton Advanced's unique value in facilitating global advanced therapy pipelines.

Porton Advanced has an extensive track record, cumulatively supporting over 60 ATMP Clinical, IND, and IIT projects in China, with orders exceeding 140 IIT batches and maintaining a flawless release success rate for all completed batches. This record highlights the company's consistent capability to meet high-quality manufacturing standards.

Porton Advanced will use all the resources, experience, and skills at the company's disposal to ensure the success of Porton Advanced's collaboration with Eureka.

About Porton Advanced
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 16 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.

Porton Advanced is committed to a customer-centric approach, providing excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.

For more information about Porton Advanced, please visit: www.portonadvanced.com.

Media Contact
[email protected]